Pfizer's dual-acting β2 agonists/muscarinic M3 antagonists

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 9, 2008, Pages 1091-1096

  Norman, Peter ^a  

^a NORMAN CONSULTING   (United Kingdom)

Author keywords

2 agonist; Asthma; Bronchodilator; COPD; M3 antagonist; MABA; Muscarinic antagonist

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC M3 RECEPTOR ANTAGONIST; PF 610 355; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PATENT; STRUCTURE ACTIVITY RELATION;

EID: 52649179472     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.9.1091     Document Type: Article

References (15)

1. Kaik G. Combined administration of ipratropium bromide (sch 1000) and fenoterol in patients with chronic obstructive airway disease. Wien Klin Wochenschr 1975;87:653-6
2. Chrischilles E, Gilden D, Kubisiak J, et al. Delivery of ipratropium and alburerol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am J Manag Care 2002;8:902-11
3. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115(3):635-41
4. Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discov Today 2007;12:479-86
5. Norman P. Dual-acting β2 agonists/muscarinic antagonists. Expert Opin Ther Patents 2006;16:1327-31
6. Theravance, Inc. Crystalline form of a biphenyl compound. WO2006023454; 2006
7. Glaxo Group Ltd. Succinic acid salt of biphenyl-2-ylcarbarnic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl) ethylaminoimethyl]}-5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester and its use for the treatment of pulmonary disorders. WO2007090859; 2007
8. Theravance, Inc. Crystalline forms of a dimethylphenyl compound. WO2007127297; 2007
9. Argenta Discovery Press Release 31 January 2007. Available from: http://www.forbion.com/downloads/AstraZeneca_sign_COPD_31_01_2007.pdf
10. Argenta Discovery Ltd. Azole and thiazole derivatives and their use. WO2007017669; 2007
11. Argenta Discovery Ltd. Bicyclo[2.2.] hept-7-ylamine derivatives and their uses. WO2007017670; 2007
12. Argenta Discovery Ltd. Nitrogen containing heterocyclic compounds useful as M3-receptor modulators. WO2008023157; 2008
13. Pfizer Ltd. Amine derivatives. WO2007107828; 2007
14. Pfizer, Inc. Pfizer Pipeline 28 February 2008. Available from: http://media.pfizer.com/files/research/pipeline/2008-0228/ pipeline_2008_0228.pdf
15. Pfizer Ltd. Compounds having beta-agonist activity. WO2005092841; 2005